Cannabis Suisse Corp. (CSUI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannabis Suisse Corp. (CSUI) trades at $0.01 with AI Score 39/100 (Grade D). Cannabis Suisse Corp. operates in the healthcare sector, focusing on the production and distribution of over-the-counter products, recreational tobacco, and medical CBD oils. Market cap: $643,197, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CSUI: CSUI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSUI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSUI: 1/1 perspectives are bearish.
How is this calculated? →Cannabis Suisse Corp. (CSUI) Healthcare & Pipeline Overview
Cannabis Suisse Corp. is a healthcare company focused on over-the-counter products, recreational tobacco, and medical CBD oils, distributed through its Swiss4Life brand and a retail network. With a high profit margin but negative gross margin, the company operates in a competitive and evolving market landscape.
What Is the Investment Thesis for CSUI?
Cannabis Suisse Corp. presents a complex investment profile. While the company boasts a high profit margin of 1469.1%, its negative gross margin of -54.7% raises concerns about operational efficiency and cost management. The company's focus on over-the-counter products, recreational tobacco, and medical CBD oils positions it in a market with both growth potential and regulatory uncertainty. Key value drivers include the expansion of its Swiss4Life brand and the establishment of strategic retail partnerships. Upcoming regulatory changes in the cannabis industry could significantly impact the company's operations and profitability. Investors should closely monitor the company's ability to improve its gross margin and navigate the evolving regulatory landscape.
Based on FMP financials and quantitative analysis
CSUI Key Highlights
- Profit Margin of 1469.1% indicates high profitability, but needs further investigation into the drivers and sustainability.
- Negative Gross Margin of -54.7% signals potential issues with cost of goods sold and pricing strategies.
- Market Cap of 643K indicates the company is a micro-cap stock with high volatility and risk.
- P/E Ratio of 5.5 suggests the stock may be undervalued compared to its earnings, but should be considered alongside other financial metrics.
- Beta of -4.65 indicates the stock is negatively correlated with the market, which may offer diversification benefits but also reflects unique company-specific risks.
Who Are CSUI's Competitors?
CSUI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSUI's Key Strengths?
- Established Swiss4Life online retail brand.
- Diversified product line including cannabis-related and health-related products.
- Early mover advantage in the emerging cannabis market.
- High reported profit margin (though offset by negative gross margin).
What Are CSUI's Weaknesses?
- Negative gross margin indicates potential issues with cost management.
- Limited market capitalization and potential liquidity concerns.
- Reliance on a relatively new and evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
What Could Drive CSUI Stock Higher?
- Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
- Strategic partnerships with major retailers to expand distribution network.
- Product diversification to include new and innovative health and wellness products.
- Potential changes in cannabis regulations that could create new market opportunities.
- Geographic expansion into new and emerging cannabis markets.
What Are the Key Risks for CSUI?
- Financial-distress signal — its Altman Z-Score of -9.87 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-6.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established pharmaceutical companies and emerging cannabis businesses.
- Evolving regulatory landscape and potential changes in cannabis laws.
- Fluctuations in commodity prices and supply chain disruptions.
- Negative public perception and potential health concerns related to cannabis and tobacco products.
- Negative gross margin indicating potential issues with cost management.
What Are the Growth Opportunities for CSUI?
- Expansion of Swiss4Life Brand: Cannabis Suisse Corp. can leverage its Swiss4Life brand to expand its online presence and direct-to-consumer sales. The global e-commerce market is projected to reach trillions of dollars in the coming years, offering a significant opportunity for growth. By investing in digital marketing and enhancing its online platform, the company can attract new customers and increase brand loyalty. Timeline: Ongoing.
- Strategic Retail Partnerships: Establishing partnerships with major retailers can significantly expand Cannabis Suisse Corp.'s distribution network and market reach. The retail industry is evolving, with consumers increasingly seeking health and wellness products in convenient locations. By securing shelf space in established retail chains, the company can increase product visibility and drive sales. Timeline: Ongoing.
- Product Diversification: Expanding the product line to include new and innovative health and wellness products can attract a broader customer base and increase revenue streams. The health and wellness market is constantly evolving, with new trends and consumer demands emerging regularly. By investing in research and development, Cannabis Suisse Corp. can create unique and differentiated products that meet the needs of its target market. Timeline: Ongoing.
- Geographic Expansion: Entering new geographic markets can significantly increase Cannabis Suisse Corp.'s growth potential. The global cannabis market is expanding rapidly, with new countries and regions legalizing cannabis for medical and recreational use. By carefully selecting target markets and adapting its products to local regulations and consumer preferences, the company can capitalize on this growth opportunity. Timeline: Upcoming.
- Regulatory Changes: Upcoming changes in cannabis regulations could create new opportunities for Cannabis Suisse Corp. As more jurisdictions legalize cannabis, the company can expand its operations and enter new markets. By staying informed about regulatory developments and adapting its business model accordingly, Cannabis Suisse Corp. can capitalize on these opportunities and gain a competitive advantage. Timeline: Ongoing.
What Opportunities Does CSUI Have?
- Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
- Strategic partnerships with major retailers to expand distribution network.
- Product diversification to include new and innovative health and wellness products.
- Geographic expansion into new and emerging cannabis markets.
What Threats Does CSUI Face?
- Increasing competition from established pharmaceutical companies and emerging cannabis businesses.
- Evolving regulatory landscape and potential changes in cannabis laws.
- Fluctuations in commodity prices and supply chain disruptions.
- Negative public perception and potential health concerns related to cannabis and tobacco products.
What Are CSUI's Competitive Advantages?
- Established Swiss4Life online retail brand.
- Network of retail distribution partners.
- Diversified product line including cannabis-related and health-related products.
- Early mover advantage in the emerging cannabis market.
What Does CSUI Do?
Cannabis Suisse Corp., formerly Geant Corp., was established in 2016 and rebranded in February 2019 to reflect its focus on cannabis-related products. Headquartered in Bell Gardens, California, the company cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. Its primary retail channel is Swiss4Life, an online brand, supplemented by a network of retailers. The product line extends beyond cannabis-related items to include health-related supplements, face masks, disinfectants, and traditional cigarettes. This diversified approach aims to capture a broader market segment within the health and wellness sector. The company's strategy involves leveraging both direct-to-consumer online sales and established retail partnerships to enhance market penetration and brand visibility. Cannabis Suisse Corp. operates within the evolving regulatory landscape of the cannabis industry, adapting its business model to comply with local and international laws.
What Products and Services Does CSUI Offer?
- Cultivates and produces over-the-counter products.
- Manufactures and distributes recreational tobacco products.
- Produces and sells medical CBD oils.
- Sells products through the Swiss4Life online retail brand.
- Distributes products through a network of retailers.
- Offers health-related supplements.
- Provides face masks and disinfectants.
- Retails cigarettes.
How Does CSUI Make Money?
- Cultivation and production of cannabis-related products.
- Direct-to-consumer sales through the Swiss4Life online platform.
- Distribution through a network of retail partners.
- Sales of health-related supplements and other wellness products.
What Industry Does CSUI Operate In?
Cannabis Suisse Corp. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, evolving regulatory landscapes, and increasing consumer demand for health and wellness products. Market trends include the growing acceptance of CBD products and the legalization of cannabis in various jurisdictions. Cannabis Suisse Corp. competes with established pharmaceutical companies and emerging cannabis businesses, navigating a complex environment of regulatory compliance and market differentiation. The company's success depends on its ability to innovate, adapt to changing regulations, and effectively market its products to a diverse consumer base.
Who Are CSUI's Key Customers?
- Consumers seeking over-the-counter health and wellness products.
- Individuals interested in recreational tobacco products.
- Patients seeking medical CBD oils for therapeutic purposes.
- Online shoppers through the Swiss4Life platform.
- Retail customers through the company's network of retail partners.
Company Profile
Cannabis Suisse Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Jacksonville, US. The company is led by CEO Scott W. Mcalister. CSUI has traded publicly since 2019.
F-Score 3/9Financial Health
Cannabis Suisse Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.87 places it in the distress zone, a signal of elevated financial risk.
ROE -6%Key Financial Metrics
Return on equity for Cannabis Suisse Corp. stands at -6.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 23.6%, showing how much profit it generates from its asset base. CSUI trades at a trailing price-to-earnings ratio of 5.52, below the Healthcare sector average of ~23x. Its free cash flow yield is -9.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 16.7%, the inverse of the P/E and a quick read on earnings relative to price.
CSUI Valuation & Market Position
With a 643K market cap, Cannabis Suisse Corp. sits in the micro-cap segment of the market. Relative to its peer group, CSUI's quantitative score of 39/100 is below the peer average of 66/100.
Net sellingInsider Activity
The most recent 5 insider filings for Cannabis Suisse Corp. break down as 5 sales and 0 purchases. On net that is roughly 20.4M shares disposed (about $220K), a signal worth weighing alongside the fundamentals.
CSUI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established Swiss4Life online retail brand.
- Diversified product line including cannabis-related and health-related products.
- Early mover advantage in the emerging cannabis market.
- High reported profit margin (though offset by negative gross margin).
Bear Case
- Negative gross margin indicates potential issues with cost management.
- Limited market capitalization and potential liquidity concerns.
- Reliance on a relatively new and evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CSUI Latest News
No recent news available for CSUI.
CSUI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSUI.
Price Targets
Wall Street price target analysis for CSUI.
CSUI MoonshotScore
What does this score mean?
The MoonshotScore rates CSUI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Scott W. Mcalister
CEO
Information on Scott W. Mcalister's background is not available in the provided context. Further research would be needed to determine his career history, education, and previous roles.
Track Record: Information on Scott W. Mcalister's track record is not available in the provided context. Further research would be needed to determine his key achievements, strategic decisions, and company milestones under his leadership.
CSUI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Suisse Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Wider bid-ask spreads and price volatility.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market and the company's specific industry.
- Consult with a financial advisor before making any investment decisions.
- Company's operational history since 2016.
- Existence of a retail brand (Swiss4Life).
- Engagement in cultivation, production, and distribution activities.
- Physical headquarters in Bell Gardens, California.
Common Questions About CSUI (Healthcare)
What does Cannabis Suisse Corp. do?
Cannabis Suisse Corp. cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. The company sells its products through its Swiss4Life online retail brand and a network of retail partners. This diversified approach allows the company to target a broad customer base within the health and wellness sector, while navigating the evolving regulatory landscape of the cannabis industry. The company's focus on both direct-to-consumer sales and retail partnerships aims to maximize market penetration and brand visibility.
What do analysts say about CSUI stock?
There is currently no available analyst coverage for Cannabis Suisse Corp. (CSUI). Given its OTC listing and micro-cap status, the company may not be actively tracked by major brokerage firms. Investors should conduct their own independent research and due diligence before making any investment decisions. Key valuation metrics to consider include the company's profit margin, gross margin, and revenue growth potential. The evolving regulatory landscape of the cannabis industry also presents both opportunities and risks for the company.
What are the main risks for CSUI?
Cannabis Suisse Corp. faces several key risks, including intense competition from established pharmaceutical companies and emerging cannabis businesses. The evolving regulatory landscape of the cannabis industry also presents significant uncertainty. Fluctuations in commodity prices and potential supply chain disruptions could impact the company's profitability. Additionally, negative public perception and potential health concerns related to cannabis and tobacco products could affect consumer demand. The company's negative gross margin also poses a significant risk, indicating potential issues with cost management and pricing strategies.
What are the key factors to evaluate for CSUI?
Cannabis Suisse Corp. (CSUI) holds an AI score of 39/100 (low). P/E: 5.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CSUI data refresh on this page?
CSUI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSUI's recent stock price performance?
Cannabis Suisse Corp. (CSUI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established Swiss4Life online retail brand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSUI overvalued or undervalued right now?
Cannabis Suisse Corp. (CSUI) trades at 5.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSUI?
Before investing in Cannabis Suisse Corp. (CSUI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market stocks are inherently riskier than exchange-listed stocks.